Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)

Inclusion Criteria: 1. Male or female patient who has received any type of chemotherapy treatment for cancer and are in remission. Participants must be diagnosed with CIPN and must be showing moderate (Grade 2, as defined by the Common Terminology Criteria for Adverse Events) symptoms of peripheral sensory neuropathy, including pain and hypersensitivity, for ≥ 3 months. Participants must have had stable symptoms of CIPN for 8 weeks before screening. Participants with any other conditions associated with neuropathy, or conditions which might confound pain assessment (e.g. other severe pain or a skin condition in the area affected by neuropathy) will be excluded. 2. Aged 18-80 years (inclusive) at the time of consent. 3. Mean daily pain score of 4-8 on the 11-point NPRS, for at least 4 days during Run-in 1. 4. A score of 0 or 1 on the ECOG Performance Status Scale. 5. Capable of self-administering topical VMD-3866 or placebo gel to the designated treatment area(s). 6. Capable of understanding the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 7. Agrees to take only the allowed rescue medication (paracetamol) for breakthrough pain, from screening and throughout the study. 8. Willing to give written consent to participate after reading the informed consent form, and after having the opportunity to discuss the trial with the investigator or their delegate. 9. Agrees to follow the contraception requirements of the trial. 10. Agrees not to donate blood or blood products during the trial and for up to 3 months after the administration of the trial medication. Exclusion Criteria: 1. Woman who is pregnant or lactating, or premenopausal woman who is sexually active and not using a reliable method of contraception. 2. History of painful conditions not associated with CIPN (e.g. frequent headache) that require administration of paracetamol or non-steroidal anti-inflammatory drugs, more than twice a week. 3. Presence of peripheral neuropathy of another etiology (e.g. alcohol, diabetes, toxins, neurotoxic treatments, hereditary, autoimmune). 4. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the participant. 5. Clinical, history or previous laboratory evidence of significant condit…